Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

7.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.4K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

491
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
491
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry01:20

Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

171
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
171
Factors Influencing Drug Absorption: Drug Dissolution01:27

Factors Influencing Drug Absorption: Drug Dissolution

401
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
401
Factors Affecting Dissolution: Particle Size and Effective Surface Area01:23

Factors Affecting Dissolution: Particle Size and Effective Surface Area

681
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
681

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using prescription drug data for timely assessments of state insurance coverage rates: a validation study.

Health affairs scholar·2026
Same author

The launch and diffusion of new patented medicines by therapeutic value.

Health affairs scholar·2026
Same author

High Cost of Cancer Medicines in the United States: Opportunities for Policy Reforms.

JCO oncology practice·2026
Same author

From Disability to Diagnosis: Baseline Findings from the Calgary Functional Movement Disorder Registry.

Movement disorders clinical practice·2026
Same author

Implications of relying on manufacturer patient support programs for access to high-cost specialty and biologic medicines: a critical qualitative study.

BMJ open·2026
Same author

Supply Chain Events and Risk of Drug Shortage in Canada.

JAMA network open·2026

Related Experiment Video

Updated: May 28, 2025

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.3K

Predicting patent challenges for small-molecule drugs: A cross-sectional study.

Ally Memedovich1, Brian Steele1, Taylor Orr1

  • 1Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Plos Medicine
|February 12, 2025
PubMed
Summary

Brand-name drug prices remain high due to delayed generic competition. Larger drug markets are more likely to face patent challenges, unlike anti-infectives or fast-track drugs. Policy interventions can promote timely generic access.

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.4K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.4K

Related Experiment Videos

Last Updated: May 28, 2025

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.3K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.4K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.4K

Area of Science:

  • Pharmaceutical economics
  • Intellectual property law
  • Drug market analysis

Background:

  • High prescription drug costs in the U.S. are sustained by brand-name manufacturers' extended market exclusivity.
  • Patent protection allows brand-name drugs a competition-free period, delaying generic entry.
  • Understanding patent challenge predictors can inform policies to encourage earlier generic competition and reduce drug prices.

Purpose of the Study:

  • To identify characteristics of brand-name drugs that predict patent challenges.
  • To assess the role of market size and other drug attributes in predicting patent challenges.
  • To inform policy development aimed at promoting timely generic competition and patient access.

Main Methods:

  • Cross-sectional study of new small-molecule drugs approved by the FDA (2007-2018).
  • Data sourced from IQVIA MIDAS, FDA's Orange Book, and FDA's Paragraph IV list.
  • Predictive models (random forest, elastic net) used to assess patent challenges within one year of eligibility.

Main Results:

  • 55% of studied drugs faced a patent challenge within the first year.
  • Market value was the strongest predictor; larger markets had more challenges.
  • Anti-infective drugs and those with fast-track approval were less likely to be challenged.

Conclusions:

  • Generic competition timeliness varies significantly across drug markets.
  • Predictive models can guide patent validity reviews and policy adjustments.
  • Addressing market size disparities can help reduce brand-name drug prices and improve access.